ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

NRSAs Renamed For Kirschstein.

June 21, 2002

Phase III Trial: Panobinostat Increases PFS by Four Months

September 26, 2014

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

April 26, 2013

In Brief: Gigliotti Named Greenwald Special Assistant; Coltman To Get ACCC Clinical Research Award

August 26, 1988

NIH May Claim BRCA1 Rights, While Myriad Files For Patent

October 7, 1994

Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.

January 21, 2005